The novel coronavirus SARS-CoV-2 was first identified in China in December 2019 and has since spread worldwide. People with Cystic Fibrosis (CF) have reduced survival mainly because of respiratory failure due to chronic pulmonary infections. Therefore, CF patients should be considered to have an increased risk of developing severe manifestations in case of SARS-CoV-2 infection. Surprisingly, the results of recent studies concerning SARS-CoV-2 infection in patients with CF show that in these patients the infection rate was lower than that of the general population. Various factors have been considered to explain a possible protective effect of CF against SARS-CoV-2 infection.
SARS-CoV-2 infection in patients with cystic fibrosian overwiew / Fainardi, V.; Longo, F.; Chetta, A.; Esposito, S.; Pisi, G.. - In: ACTA BIO-MEDICA DE L'ATENEO PARMENSE. - ISSN 0392-4203. - 91:3(2020), pp. 1-5. [10.23750/abm.v91i3.10391]
SARS-CoV-2 infection in patients with cystic fibrosian overwiew
Fainardi V.;Longo F.;Chetta A.;Esposito S.;
2020-01-01
Abstract
The novel coronavirus SARS-CoV-2 was first identified in China in December 2019 and has since spread worldwide. People with Cystic Fibrosis (CF) have reduced survival mainly because of respiratory failure due to chronic pulmonary infections. Therefore, CF patients should be considered to have an increased risk of developing severe manifestations in case of SARS-CoV-2 infection. Surprisingly, the results of recent studies concerning SARS-CoV-2 infection in patients with CF show that in these patients the infection rate was lower than that of the general population. Various factors have been considered to explain a possible protective effect of CF against SARS-CoV-2 infection.File | Dimensione | Formato | |
---|---|---|---|
Fainardi et al_SARS-CoV-2 Infection in patients with cystic fibrosis. An overwiew ACTA2020.pdf
accesso aperto
Descrizione: Full Text
Tipologia:
Versione (PDF) editoriale
Licenza:
Creative commons
Dimensione
305.12 kB
Formato
Adobe PDF
|
305.12 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.